Defactinib: Interim Phase I data

Interim data from 9 patients in an open-label, dose-escalation, Japanese Phase I trial showed that twice-daily doses of 200, 400 and 600 mg oral defactinib led to 2 cases of stable disease lasting for >=24 weeks. All doses were well tolerated with no dose-limiting toxicities (DLTs) reported. The most common treatment-related adverse events were grade 1/2 elevated bilirubin count, fatigue, decreased appetite and diarrhea. Data were presented at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics meeting in Barcelona. ...